Advertisement

Methylation of cation–chloride cotransporters NKCC1 and KCC2 in patients with juvenile myoclonic epilepsy

  • Fatma GençEmail author
  • Murat Kara
  • Yasemin Ünal
  • Elif Uygur Küçükseymen
  • Yasemin Biçer Gömceli
  • Taner Kaynar
  • Kürşad Tosun
  • Gülnihal Kutlu
Original Article

Abstract

The etiology of juvenile myoclonic epilepsy (JME) is still unknown and the process of elaboration of multiple genetic mechanisms is ongoing. The aim of this study was to investigate the potential role of NKCC1 (SCL12A2) and KCC2 (SCL12A5) in JME by comparing their DNA methylation status in patients with JME versus healthy controls. Forty-nine patients with JME and 39 healthy individuals were compared for DNA methylation at the 5CpG islands. A total of 71 (81%) samples were found to have methylation in the NKCC1 gene, 36 (73%) from patients and 35 (90%) from healthy individuals. Out of the KCC2 samples, 50 (57%) were found to have methylation, 33 (67%) from patients and 17 (44%) from healthy individuals. In patients with JME, methylation of NKCC1 (73%) was lower than its methylation in the controls (90%) (p = 0.047). On the other hand, methylation of KCC2 in patients with JME (67%) was greater than the methylation in the controls (44%) (p = 0.022). Twenty-eight patients were treated with VPA and ongoing medications were not found to be associated with methylation (p > 0.05). In the present study, we determined significantly lower NKCC1 DNA methylation and significantly higher KCC2 DNA methylation levels in patients with JME compared with the healthy controls. This implies that NKCC1 expression can be higher and KCC2 expression can be reduced in affected people. Further studies that investigate the potential effect of DNA methylation mechanisms regulating gene expression on seizure activity and how they change JME network activity will be helpful.

Keywords

Juvenile myoclonic epilepsy Epigenetic DNA methylation Cation–chloride cotransporters NKCC1 (SCL12A2), KCC2 (SCL12A5) 

Notes

Compliance with ethical standards

The study was approved by the Ethics Committee of Antalya Education and Research Hospital.

Conflict of interest

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Camfield CS, Striano P, Camfield PR (2013) Epidemiology of juvenile myoclonic epilepsy. Epilepsy Behav 28(Suppl 1):S15–S17.  https://doi.org/10.1016/j.yebeh.2012.06.024 CrossRefGoogle Scholar
  2. 2.
    Dedei Daryan M, Güveli BT, Baslo SA, Mulhan K, Sarı H, Balçık ZE, Ataklı D (2018) Prevalence and clinical characteristics of headache in juvenile myoclonic epilepsy: experience from a tertiary epilepsy center. Neurol Sci 39(3):519–525.  https://doi.org/10.1007/s10072-017-3232-y CrossRefGoogle Scholar
  3. 3.
    Baykan B, Wolf P (2017) Juvenile myoclonic epilepsy as a spectrum disorder: a focused review. Seizure 49:36–41.  https://doi.org/10.1016/j.seizure.2017.05.011 CrossRefGoogle Scholar
  4. 4.
    Desai D, Desai S, Jani T (2016) Juvenile myoclonic epilepsy in rural Western India: not yet a benign syndrome. Epilepsy Res Treat 2016:1435150.  https://doi.org/10.1155/2016/1435150 Google Scholar
  5. 5.
    Kobow K, Blümcke I (2018) Epigenetics in epilepsy. Neurosci Lett 667:40–46.  https://doi.org/10.1016/j.neulet.2017.01.012
  6. 6.
    International League Against Epilepsy Consortium on Complex Epilepsies (2018) Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat Commun 9(1):5269.  https://doi.org/10.1038/s41467-018-07524-z CrossRefGoogle Scholar
  7. 7.
    Younus I, Reddy DS (2017) Epigenetic interventions for epileptogenesis: a new frontier for curing epilepsy. Pharmacol Ther 177:108–122.  https://doi.org/10.1016/j.pharmthera.2017.03.002 CrossRefGoogle Scholar
  8. 8.
    Li XQ, Guo YY, De W et al (2012) DNA methylation and microRNAs in cancer. World J Gastroenterol 18(9):882–888.  https://doi.org/10.3748/wjg.v18.i9.882 CrossRefGoogle Scholar
  9. 9.
    Pathak S, Miller J, Morris EC, Stewart WCL, Greenberg DA (2018) DNA methylation of the BRD2 promoter is associated with juvenile myoclonic epilepsy in Caucasians. Epilepsia 59(5):1011–1019.  https://doi.org/10.1111/epi.14058 CrossRefGoogle Scholar
  10. 10.
    Hirose C (2014) Mutant GABAA receptor subunits in genetic (idiopathic) epilepsy. Prog Brain Res 213:55–85.  https://doi.org/10.1016/B978-0-444-63326-2.00003-X CrossRefGoogle Scholar
  11. 11.
    Watanabe M, Fukuda A (2015) Development and regulation of chloride homeostasis in the central nervous system. Front Cell Neurosci 9:371.  https://doi.org/10.3389/fncel.2015.00371 CrossRefGoogle Scholar
  12. 12.
    Craiu D (2013) What is special about the adolescent (JME) brain? Epilepsy Behav 28(Suppl 1):S45–S51.  https://doi.org/10.1016/j.yebeh.2012.12.008 CrossRefGoogle Scholar
  13. 13.
    Hattingen E, Lückerath C, Pellikan S, Vronski D, Roth C (2014) Frontal and thalamic changes of GABA concentration indicate dysfunction of thalamofrontal networks in juvenile myoclonic epilepsy. Epilepsia 55(7):1030–1037.  https://doi.org/10.1111/epi.12656 CrossRefGoogle Scholar
  14. 14.
    González MI (2016) Regulation of the cell surface expression of chloride transporters during epileptogenesis. Neurosci Lett 628:213–218.  https://doi.org/10.1016/j.neulet.2016.06.042 CrossRefGoogle Scholar
  15. 15.
    Kasteleijn-Nolst Trenité DG, Schmitz B, Janz D, Delgado-Escueta AV, Thomas P et al (2013) Consensus on diagnosis and management of JME: From founder’s observations to current trends. Epilepsy Behav 28(Suppl 1):S87–S90.  https://doi.org/10.1016/j.yebeh.2012.11.051 CrossRefGoogle Scholar
  16. 16.
    Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology. 2005–2009. Epilepsia 51(4):676–685.  https://doi.org/10.1111/j.1528-1167.2010.02522.x CrossRefGoogle Scholar
  17. 17.
    Dalton SR, Bellacosa A (2012) DNA demethylation by TDG. Epigenomics 4(4):459–467.  https://doi.org/10.2217/epi.12.36 CrossRefGoogle Scholar
  18. 18.
    Song J, Teplova M, Ishibe-Murakami S, Patel DJ (2012) Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science 335:709–712.  https://doi.org/10.1126/science.1214453 CrossRefGoogle Scholar
  19. 19.
    Szyf M, Knox DJ, Milutinovic S, Slack AD, Araujo FD (2000) How does DNA methyltransferase cause oncogenic transformation? Ann N Y Acad Sci 910:156–174CrossRefGoogle Scholar
  20. 20.
    Zhu L, Polley N, Mathews GC, Delpire E (2008) NKCC1 and KCC2 prevent hyperexcitability in the mouse hippocampus. Epilepsy Res 79(2–3):201–212.  https://doi.org/10.1016/j.eplepsyres.2008.02.005 CrossRefGoogle Scholar
  21. 21.
    Taskıran E, Bebek N (2015) Drug resistance and resistance mechanisms in epilepsy. Epilepsi 21(2):43–53.  https://doi.org/10.5505/epilepsi.2015.50570
  22. 22.
    Blaesse P, Airaksinen MS, Rivera C, Kaila K (2009) Cation-chloride cotranspoters and neuronal function. Neuron 61:820–838.  https://doi.org/10.1016/j.neuron.2009.03.003 CrossRefGoogle Scholar
  23. 23.
    Li X, Zhou J, Chen Z, Chen S, Zhu F (2008) Long-term expressional changes of Na+ -K+ -Cl- co-transporter 1 (NKCC1) and K+ -Cl- co-transporter 2 (KCC2) in CA1 region of hippocampus following lithium-pilocarpine induced status epilepticus (PISE). Brain Res 1221:141–146.  https://doi.org/10.1016/j.brainres.2008.04.047 CrossRefGoogle Scholar
  24. 24.
    Palma E, Amici M, Sobrero F, Spinelli G, Di Angelantonio S (2006) Anomalous levels of Cl- transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA excitatory. Proc Natl Acad Sci U S A 103(22):8465–8468.  https://doi.org/10.1073/pnas.0602979103 CrossRefGoogle Scholar
  25. 25.
    Gómez-Lira G, Mendoza-Torreblanca JG, Granados-Rojas L (2011) Ketogenic diet does not change NKCC1 and KCC2 expression in rat hippocampus. Epilepsy Res 96(1–2):166–171.  https://doi.org/10.1016/j.eplepsyres.2011.05.017 CrossRefGoogle Scholar
  26. 26.
    Lösher W, Puskarjov M, Kaila K (2013) Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology 69:62–74.  https://doi.org/10.1016/j.neuropharm.2012.05.045
  27. 27.
    Jakovcevski M, Akbarian S (2012) Epigenetic mechanisms in neurological disease. Nat Med 18:1194–1204.  https://doi.org/10.1038/nm.2828 CrossRefGoogle Scholar
  28. 28.
    Belhedi N, Perroud N, Karege F, Vessaz M, Malafosse A, Salzmann A (2014) Increased CPA6 promoter methylation in focal epilepsy and in febrile seizures. Epilepsy Res 108:144–148.  https://doi.org/10.1016/j.eplepsyres.2013.10.007
  29. 29.
    Illingworth R, Kerr A, Desousa D et al (2008) A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol 6(1):e22.  https://doi.org/10.1371/journal.pbio.0060022

Copyright information

© Fondazione Società Italiana di Neurologia 2019

Authors and Affiliations

  1. 1.Antalya Training and Research Hospital, Department of NeurologyAntalyaTurkey
  2. 2.IstanbulTurkey
  3. 3.Faculty of Medicine Department of NeurologyMuğla Sıtkı Koçman UniversityMuğlaTurkey
  4. 4.Neuromodulation Center, Spaulding Rehabilitation HospitalHarvard Medical SchoolBostonUSA
  5. 5.Sitogen Biomedical and Laboratory Systems Industrial Trade Limited CompanyİstanbulTurkey
  6. 6.Siena CollegeLoudonvilleUSA
  7. 7.Faculty of Medicine Department of Neurology and Clinical NeurophysiologyMuğla Sıtkı Koçman UniversityMuğlaTurkey

Personalised recommendations